Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. by Elstein, D, Hollak, C, Aerts, J, van Weely, S, Maas, M, Cox, T, Lachmann, R, Hrebicek, M, Platt, F, Butters, T, Dwek, R, Zimran, A

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. by Cox, T, Lachmann, R, Hollak, C, Aerts, J, van Weely, S, Hrebícek, M, Platt, F, Butters, T, Dwek, R, Moyses, C, Gow, I, Elstein, D, Zimran, A

Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. by Platt, F, Jeyakumar, M, Andersson, U, Priestman, D, Dwek, R, Butters, T, Cox, T, Lachmann, R, Hollak, C, Aerts, J, Van Weely, S, Hrebícek, M, Moyses, C, Gow, I, Elstein, D, Zimran, A